Cardiovascular risk and body-fat abnormalities in HIV-infected adults.
Grinspoon
Steven
S
Program in Nutritional Metabolism and the Neuroendocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston 02114, USA. sgrinspoon@partners.org
Carr
Andrew
A
D044966:Anti-Retroviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects*; D001823:Body Composition / Q000187:drug effects; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D039682:HIV-Associated Lipodystrophy Syndrome / Q000139:chemically induced / Q000628:therapy*; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy / Q000209:etiology*; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D007333:Insulin Resistance; D018570:Risk Assessment; D012307:Risk Factors
D044966:Anti-Retroviral Agents; D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents